It is a differentiation game: STAT5 in a new role

Por Maurer, Barbara, Farlik, Matthias, Sexl, Veronika
Publicado no Cell Death Differ (2017)

Therapeutic Vulnerabilities in FLT3-Mutant AML Unmasked by Palbociclib

Por Uras, Iris Z., Maurer, Barbara, Nebenfuehr, Sofie, Zojer, Markus, Valent, Peter, Sexl, Veronika
Publicado no Int J Mol Sci (2018)

Emerging therapeutic targets in myeloproliferative neoplasms and peripheral T-cell leukemia and lymphomas

Por Orlova, Anna, Wingelhofer, Bettina, Neubauer, Heidi A., Maurer, Barbara, Berger-Becvar, Angelika, Keserű, György Miklós, Gunning, Patrick T., Valent, Peter, Moriggl, Richard
Publicado no Expert Opin Ther Targets (2017)

Dual modality optical coherence and whole-body photoacoustic tomography imaging of chick embryos in multiple development stages

Por Liu, Mengyang, Maurer, Barbara, Hermann, Boris, Zabihian, Behrooz, Sandrian, Michelle G., Unterhuber, Angelika, Baumann, Bernhard, Zhang, Edward Z., Beard, Paul C., Weninger, Wolfgang J., Drexler, Wolfgang
Publicado no Biomed Opt Express (2014)

Pharmacologic inhibition of STAT5 in acute myeloid leukemia

Por Wingelhofer, Bettina, Maurer, Barbara, Heyes, Elizabeth C., Cumaraswamy, Abbarna A., Berger-Becvar, Angelika, de Araujo, Elvin D., Orlova, Anna, Freund, Patricia, Ruge, Frank, Park, Jisung, Tin, Gary, Ahmar, Siawash, Lardeau, Charles-Hugues, Sadovnik, Irina, Bajusz, Dávid, Keserű, György Miklós, Grebien, Florian, Kubicek, Stefan, Valent, Peter, Gunning, Patrick T., Moriggl, Richard
Publicado no Leukemia (2018)

STAT5B(N642H) is a driver mutation for T cell neoplasia

Por Pham, Ha Thi Thanh, Maurer, Barbara, Prchal-Murphy, Michaela, Grausenburger, Reinhard, Grundschober, Eva, Javaheri, Tahereh, Nivarthi, Harini, Boersma, Auke, Kolbe, Thomas, Elabd, Mohamed, Halbritter, Florian, Pencik, Jan, Kazemi, Zahra, Grebien, Florian, Hengstschläger, Markus, Kenner, Lukas, Kubicek, Stefan, Farlik, Matthias, Bock, Christoph, Valent, Peter, Müller, Mathias, Rülicke, Thomas, Sexl, Veronika, Moriggl, Richard
Publicado no J Clin Invest (2017)

Increased survival and cell cycle progression pathways are required for EWS/FLI1-induced malignant transformation

Por Javaheri, Tahereh, Kazemi, Zahra, Pencik, Jan, Pham, Ha TT, Kauer, Maximilian, Noorizadeh, Rahil, Sax, Barbara, Nivarthi, Harini, Schlederer, Michaela, Maurer, Barbara, Hofbauer, Maximillian, Aryee, Dave NT, Wiedner, Marc, Tomazou, Eleni M, Logan, Malcolm, Hartmann, Christine, Tuckermann, Jan P, Kenner, Lukas, Mikula, Mario, Dolznig, Helmut, Üren, Aykut, Richter, Günther H, Grebien, Florian, Kovar, Heinrich, Moriggl, Richard
Publicado no Cell Death Dis (2016)

Correction: Increased survival and cell cycle progression pathways are required for EWS/FLI1-induced malignant transformation

Por Javaheri, Tahereh, Kazemi, Zahra, Jan Pencik, Pham, Ha T. T., Kauer, Maximilian, Noorizadeh, Rahil, Sax, Barbara, Nivarthi, Harini, Schlederer, Michaela, Maurer, Barbara, Hofbauer, Maximillian, Aryee, Dave N. T., Wiedner, Marc, Tomazou, Eleni M., Logan, Malcolm, Hartmann, Christine, Tuckermann, Jan P., Kenner, Lukas, Mikula, Mario, Dolznig, Helmut, Üren, Aykut, Richter, Günther H., Grebien, Florian, Kovar, Heinrich, Moriggl, Richard
Publicado no Cell Death Dis (2018)